ImmunoTargets and Therapy is an international journal that aims to present and publish basic and clinical research on the aspects of immunology in health and disease. ImmunoTargets and Therapy is primarily focused on the immunological basis of disease and explores the evidence behind new and existing immunotherapies in terms of improving outcomes and, importantly, will seek to define their usage in terms of ultimate uptake and acceptance by the patient and health care professional.
Specific Topics covered in this journal include:
Biology and pathophysiology of the immune system in health and disease
Immunological basis and immunological markers of diseases
Potential targets for immune based therapy including therapeutic and prophylactic vaccines
Novel and improved targets for immunodiagnostics and immunomonitoring
Treatment protocols to improve management of patient with immune-mediated diseases
Impact of management programs and new therapeutic agents
Protocols on patient perspectives such as quality of life, adherence, and satisfaction
Studies based on in-vitro research need to be supported by comprehensive experimental validation of results.
ImmunoTargets and Therapy will no longer consider meta-analyses for publication.
Journal metrics
Usage
29K annual downloads/views
Citation metrics
6.2 (2023) Impact Factor
Q1 Impact Factor Best Quartile
8.1 (2023) 5 year IF
16.5 (2023) CiteScore (Scopus)
Q1 CiteScore Best Quartile
1.772 (2023) SNIP
2.140 (2023) SJR
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors
who are deciding where to submit their next manuscript for publication.
However, any one metric only tells a part of the story of a journal’s
quality and impact. Each metric has its limitations which means that it
should never be considered in isolation, and metrics should be used to
support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside
other qualitative factors such as a journal’s aims & scope, its
readership, and a review of past content published in the journal. In
addition, a single article should always be assessed on its own merits and
never based on the metrics of the journal it was published in.
Usage and acceptance rate data above are for the last full calendar year
and are updated annually in February. Speed data is updated every six
months, based on the prior six months. Citation metrics are updated
annually mid-year. Please note that some journals do not display all of
the following metrics
(find out why).
Usage:
the total number of times articles in the journal were viewed by users
of Taylor & Francis Online in the previous calendar year, rounded to the
nearest thousand.
Citation Metrics
Impact Factor*:
the average number of citations received by articles published in the
journal within a two-year window. Only journals in the Clarivate Science
Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI),
Arts and Humanities Citation Index (AHCI) and the Emerging Sources
Citation Index (ESCI) have an Impact Factor.
Impact Factor Best Quartile*:
the journal’s highest subject category ranking in the Journal Citation
Reports. Q1 = 25% of journals with the highest Impact Factors.
5 Year Impact Factor*:
the average number of citations received by articles in the journal
within a five-year window.
CiteScore (Scopus)†:
the average number of citations received by articles in the journal over
a four-year period.
CiteScore Best Quartile†:
the journal’s highest CiteScore ranking in a Scopus subject category. Q1
= 25% of journals with the highest CiteScores.
SNIP
(Source Normalized Impact per Paper):
the number of citations per paper in the journal, divided by citation
potential in the field.
SJR
(Scimago Journal Rank):
Average number of (weighted) citations in one year, divided by the
number of articles published in the journal in the previous three years.
Speed/acceptance
From submission to first decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision. Based on manuscripts receiving a
first decision in the last six months.
From submission to first post-review decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision if it is sent out for peer review.
Based on manuscripts receiving a post-review first decision in the last
six months.
From acceptance to online publication:
the average (median) number of days from acceptance of a manuscript to
online publication of the Version of Record. Based on articles published
in the last six months.
Acceptance rate:
articles accepted for publication by the journal in the previous
calendar year as percentage of all papers receiving a final decision.
Professor Michael Shurin, Pathology, University of Pittsburgh Medical Center, United States
Associate Editors-in-Chief:
Professor Jadwiga Jablonska, Otolaryngology, University Hospital Essen, Germany
Dr Flavio Salazar Onfray, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile
Dr Sarah Wheeler, Pathology, University of Pittsburgh, United States
Editorial Board:
Dr Natalia Aptsiauri, Biochemistry, Molecular Biology and Immunology, University of Granada Medical School, Spain
Professor Dr Subashchandrabose Chinnathambi, Clinical Biochemistry Unit, National Institute of Mental Health and Neuro Sciences (NIMHANS), India
Dr Girdhari Lal, Ph.D. Senior Scientist at National Centre for Cell Science, Pune India. His laboratory is interested in understanding the cellular and molecular basis of Inflammation and tolerance in cancer and autoimmunity, National Centre for Cell Science, India.
Professor Azzam A Maghazachi, Clinical Sciences, University of Sharjah, United Arab Emirates
Professor Qizhi (Cathy) Yao, Molecular Virology and Microbiology, Baylor College of Medicine, United States
Abstracting and indexing
ImmunoTargets and Therapy is indexed/tracked/covered by the following services:
Directory of Open Access Journals (DOAJ)
EMBASE (Elsevier)
Pubmed (NLM)
PubMed Central Selective Deposit Medicine & Health (NLM)
Scopus (Elsevier)
Open access
ImmunoTargets and Therapy is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
Increase the discoverability and readership of your article
Make an impact and reach new readers, not just those with easy access to a research library
Freely share your work with anyone, anywhere
Comply with funding mandates and meet the requirements of your institution, employer or funder
Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110817/Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
![BioTechniques: Stay up to date with the hottest topics in the life sciences...]({"type":"image" , "src" : "/sda/112459/journalad-promotion-biotechniques.png"})